← All trials
NCT06067828
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 24, 2023
- Primary completion
- Aug 24, 2025
- Completion date
- Aug 25, 2025
- First posted
- Oct 5, 2023
- Last posted
- Dec 28, 2023
- Enrollment
- 180
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.